Skip to main content

Opportunities for Financing Your Company Through Series B and Beyond

Monday, February 26, 2024
Majestic Complex
This session will begin with a presentation from the HSBC Innovation Banking 2023 annual report. The report shows investment pace similar to 2H 2022, with crossovers returning to lead later-stage deals in 2H 2023. While Series B means “Be in the clinic” there still is a small opening for strong pre-clinical stories to get funded. Corporates, growth/traditional VCs, and sovereign wealth join crossovers to create a (smaller than 2021 but) still healthy group of investors willing to put new capital to work. After the overview, investors and executives will discuss venture and alternative financing opportunities in 2024 as companies seek to continue development of important therapies.
Kate Walsh, Managing Director, Life Science and Healthcare - HSBC Bank USA
Ellen Hukkelhoven, Head of Biotechnology Investments - Perceptive Advisors
Jonathan Norris, Managing Director - HSBC Innovation
Alethia Young, Chief Financial Officer - Bicycle Therapeutics

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.